Trial
NCT04217317
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
National Cancer Institute (NCI)
Condition
Relapsed T-Cell Lymphoma
Intervention
CPI 613
Why stopped
Low accruals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-02